9 results about "Aminopropionitrile" patented technology

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

This invention provides a method for synthesizing 4-methoxypyrrole derivatives, relating to the field of organic chemical intermediate synthesis technology. The 4-methoxypyrrole derivative is prepared by first reacting m-difluorobenzene as a starting material with oxaloyl chloride monoester under Lewis acid catalysis. The reaction product then undergoes cyclization with aminopropionitrile under alkaline conditions. The subsequent product reacts with methanol in a boron trifluoride complex, followed by methylation with a methylating agent under alkaline conditions. This invention overcomes the shortcomings of existing technologies, providing a simple, low-cost, and easily industrialized method for preparing 4-methoxypyrrole derivatives. It offers advantages such as readily available raw materials, high yield, good quality, simple operation, and suitability for industrial production.

The invention discloses a production process of N, N-dimethyl propane diamine, which comprises the following steps: carrying out addition reaction on dimethylamine and acrylonitrile in the absence of a catalyst to obtain an intermediate dimethylaminopropionitrile and a small amount of addition byproducts; carrying out hydrogenation reaction on the intermediate under the conditions of a hydrogenation catalyst, an alkaline auxiliary agent and an alcohol solvent to produce a target product N, N-dimethyl propane diamine, a small amount of byproducts such as tetramethyl propane diamine (TMAPA) and propylamine, and reaction slurry containing the hydrogenation catalyst; reaction slurry enters a catalyst filter to be filtered; carrying out flash evaporation on the filtered reaction clear liquid in a hot high-pressure separation tank; further separating a liquid-phase reaction product in the light component removal tower; and further separating the mixture in a product refining tower to obtain a qualified product N, N-dimethyl propane diamine, and the like. According to the production process, the qualified product N, N-dimethyl propane diamine can be continuously produced, the purity of the product is 99.5% or above, and the yield is 95% or above.

The application discloses a method for efficiently preparing beta-amino propionic acid calcium from beta-amino propionitrile, and comprises the following steps: beta-amino propionitrile and a calcium salt solution are reacted in the presence of a catalyst and an additive, and microwave radiation is used to promote the reaction; after the reaction solution is filtered and deaminated, the solution is concentrated, cooled and alcohol crystallized to obtain beta-amino propionic acid calcium crystals which can be used for the production of calcium pantothenate; wherein the catalyst is a transition metal complex, and the additive is a phase transfer catalyst or a buffer metal salt. The application has the advantages of simple process, high yield and high reaction efficiency.

The invention relates to a method for synthesizing a diaveridine intermediate, which comprises the following steps: (a) adding dimethyl sulfoxide, potassium hydroxide and 3-dimethylaminopropionitrile into a reaction container, and heating to 65-75 DEG C; then adding veratraldehyde, and stirring to react for 2-3 hours to obtain a first reaction solution; and (b) adding ethanol and aniline into the first reaction solution, then dropwise adding an acid-containing solution, carrying out heat preservation reaction at 75-85 DEG C for 2-3 hours, cooling, crystallizing, and drying to obtain the diaveridine intermediate. Therefore, the side reaction for synthesizing the diaveridine intermediate can be inhibited, so that the reaction conditions are simplified, and the yield of the product is improved.

The application provides a beta-amino propionitrile purification device, and belongs to the technical field of purification devices. The device comprises a distillation tower, a steam outlet pipe is arranged at the top of the distillation tower, the steam outlet pipe is connected with a heat exchange box, a first serpentine pipe and a second serpentine pipe are arranged in the heat exchange box, a first discharge pipe is arranged on the heat exchange box, a reflux pipe is arranged at the bottom of the heat exchange box, one end of the first serpentine pipe is connected with an ammonia removal box, a second discharge pipe is arranged at the bottom of the ammonia removal box, the second discharge pipe is connected with the distillation tower, an exhaust pipe is arranged at the top of the ammonia removal box, a first heating element is arranged in the ammonia removal box, 3-amino propionitrile low-temperature mixture generated in the reaction is heated through the heat exchange box, then is further heated and ammonia is removed through the ammonia removal box, so that the mixture is heated and ammonia is removed by using high-temperature steam in the distillation tower, energy consumption is reduced, the removed ammonia can be made into ammonia water and reused, and raw material waste is reduced.

Use of p55γ as a therapeutic target for aortic dissection (AD) is provided, belonging to the technical field of biomedicine. Over-expression of the p55γ inhibits formation of the AD and degradation of elastic fibers in mice induced by β-aminopropionitrile fumarate (BAPN); whereas knockdown of the p55γ in vascular smooth muscle cells (VSMCs) promotes the formation of the AD and the degradation of the elastic fibers induced by the BAPN. Mechanistically, the p55γ plays a role by maintaining phenotypic switching of the VSMCs, and knocking down the p55γ promotes phenotypic switching of the VSMCs from a contractile phenotype to a synthetic phenotype. The p55γ is used as a target in screening a drug for prevention and / or treatment of AD, such that a selected drug can effectively prevent and / or treat the AD, thus providing a new target for treating the AD.

This invention discloses a four-step method for preparing 4-trifluoromethylnicotinic acid from 2-chloroacrylonitrile, belonging to the field of chemical pharmaceutical intermediate synthesis. Using 2-chloroacrylonitrile as a raw material, an amination reagent is added to prepare 3-amino-2-chloropropionitrile, which is then reacted with 4-ethoxy-1,1,1-trifluorobut-3-en-2-one to prepare 2-chloro-3-((4,4,4-trifluoro-3-oxobut-1-en-1-yl)amino)propionitrile. Finally, a two-step method involving cyclization and hydrolysis with the addition of an alkali yields the target product 4-trifluoromethylnicotinic acid. This method yields a product with high purity and high yield, low raw material cost, a short and efficient route, mild reaction conditions, and is environmentally friendly, making it more suitable for industrial production.

The application provides application of an SLFN5 inhibitor in preparation of a drug for preventing and / or treating aortic dissection, and belongs to the technical field of aortic dissection prevention and treatment.The application provides application of an SLFN5 inhibitor in preparation of a drug for preventing and / or treating aortic dissection, and first proposes that SLFN5 genes or SLFN5 proteins can be used as target points for preparation of a drug for preventing and / or treating aortic dissection.The application first proposes that overexpression of SLFN5 promotes formation of aortic dissection and degradation of elastic fibers of a mouse induced by 3-aminopropionitrile fumarate (BAPN); and knockdown of SLFN5 inhibits formation of aortic dissection and degradation of elastic fibers of a mouse induced by BAPN.The application uses SLFN5 as a target point for preparation of a drug for preventing and / or treating aortic dissection, can effectively prevent and / or treat aortic dissection, and provides a new target point for treating aortic dissection.